Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
aap Implantate AG (AAQ1.DE)
Berlin, DE
Operating as a medical technology firm, aap Implantate AG specializes in the development, manufacturing, and commercialization of orthopedic trauma devices. The company's market presence spans Germany, the United States, and various international regions. Its primary offerings feature LOQTEQ, an advanced anatomical plating system crucial for fracture treatment, in addition to a diverse selection of cannulated screws, conventional plates, and standard screws. Products are distributed under the 'aap' brand, reaching customers directly, including hospitals, purchasing syndicates, and hospital groups, as well as indirectly via its network of distributors. aap Implantate AG was founded in 1990 and maintains its corporate headquarters in Berlin, Germany.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -4.33% | -0.50% | +40.14% | +46.32% | +45.26% | +50.76% | +73.04% | -28.93% | -85.28% | -97.60% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+2.4% Q2'25: -2.0% (vs Q2'24)
-
EPS growth Medical - Devices: +28.5%+48.7% ★ Q2'25: +21.7% (vs Q2'24)
-
FCF margin FCF growth · Medical - Devices: +30.9%-20.0% Q2'25: -5.8% (vs Q2'24)
-
EBIT margin Medical - Devices: +6.2%-20.0% Q2'25: -15.3% (vs Q2'24)
-
ROIC Medical - Devices: +3.3%— Q2'25: -22.0% (vs Q2'24)
-
Share dilution Medical - Devices: 0.0%+41.0% Q2'25: +41.0% (vs Q2'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×— Q2'25: -0.96× (vs Q2'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
12.28M
est: 28.70M (-57.2%)
|
10.49M
est: 31.80M (-67.0%)
|
10.90M
est: 10.90M (+0.0%)
|
10.78M
est: 10.95M (-1.5%)
|
11.74M
est: 11.00M (+6.7%)
|
9.33M
est: 9.40M (-0.8%)
|
12.17M
est: 12.20M (-0.3%)
|
11.52M
est: 11.70M (-1.6%)
|
11.48M
est: 11.30M (+1.6%)
|
12.20M
est: 13.00M (-6.1%)
|
12.50M
est: 15.00M (-16.7%)
|
| EBITDA |
-6.06M
est: -6.63M (+8.5%)
|
-7.87M
est: -7.35M (-7.2%)
|
-7.47M
est: -2.52M (-196.7%)
|
-5.89M
est: -2.53M (-133.0%)
|
-6.44M
est: -2.54M (-153.6%)
|
-5.40M
est: -2.17M (-148.8%)
|
-520.0K
est: -2.82M (+81.5%)
|
-1.57M
est: -2.70M (+42.0%)
|
-3.43M
est: -2.61M (-31.5%)
|
-1.19M
est: -3.00M (+60.2%)
|
-2.50M
est: -3.46M (+27.8%)
|
| EBIT |
-9.09M
est: -11.91M (+23.7%)
|
-9.77M
est: -13.20M (+26.0%)
|
-9.25M
est: -4.52M (-104.6%)
|
-7.62M
est: -4.54M (-67.7%)
|
-8.51M
est: -4.56M (-86.4%)
|
-8.48M
est: -3.90M (-117.3%)
|
-2.36M
est: -5.06M (+53.3%)
|
-3.24M
est: -4.86M (+33.2%)
|
-5.05M
est: -4.69M (-7.6%)
|
-3.06M
est: -5.39M (+43.4%)
|
-2.50M
est: -6.22M (+59.8%)
|
| Net Income |
-5.29M
est: -9.81M (+46.1%)
|
-9.27M
est: -6.25M (-48.4%)
|
-9.27M
est: -17.84M (+48.0%)
|
-7.67M
est: -24.98M (+69.3%)
|
-19.44M
est: -27.27M (+28.7%)
|
-8.94M
est: -23.54M (+62.0%)
|
-2.52M
est: -5.62M (+55.1%)
|
-2.56M
est: -4.54M (+43.5%)
|
-5.13M
est: -4.34M (-18.1%)
|
-3.63M
est: -2.78M (-30.5%)
|
-2.60M
est: -973.8K (-167.0%)
|
| SGA |
4.44M
est: 11.52M (-61.5%)
|
5.05M
est: 12.76M (-60.5%)
|
5.36M
est: 4.38M (+22.5%)
|
5.24M
est: 4.40M (+19.1%)
|
5.47M
est: 4.42M (+23.9%)
|
4.34M
est: 3.77M (+14.9%)
|
4.55M
est: 4.90M (-7.0%)
|
4.26M
est: 4.70M (-9.3%)
|
4.74M
est: 4.54M (+4.4%)
|
4.70M
est: 5.22M (-9.9%)
|
—
est: 6.02M (-100.0%)
|
| EPS |
-1.56
est: -1.00 (-56.8%)
|
-2.71
est: -0.63 (-328.0%)
|
-2.93
est: -1.81 (-62.0%)
|
-2.46
est: -2.53 (+2.9%)
|
-5.59
est: -2.76 (-102.2%)
|
-2.57
est: -2.39 (-7.7%)
|
-0.55
est: -0.57 (+3.5%)
|
-0.43
est: -0.46 (+6.5%)
|
-0.62
est: -0.44 (-40.9%)
|
-0.37
est: -0.20 (-85.0%)
|
-0.19
est: -0.07 (-171.4%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-26 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-25 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-19 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-18 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-15 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-14 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-13 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-12 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-11 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-08 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-04 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-29 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Rubino Di Girolamo | Chairman of the Management Board & Chief Executive Officer | 205.0K | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AAQ1.DE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
